This clinical trial is focused on patients who have experienced lower limb trauma and require immobilization, such as a brace or cast. The study aims to compare the effectiveness of two treatments in preventing blood clots, which are known as thromboembolic events. The treatments being compared are Rivaroxaban, a medication taken orally in the form of a tablet, and low-molecular weight heparin (LMWH), which is administered through injections. The main goal is to determine if Rivaroxaban is not less effective than LMWH in preventing these blood clots in patients who are at high risk according to a specific score called the TRiP(cast) score.

Participants in the study will receive either Rivaroxaban or LMWH for a period of up to 50 days. The study will monitor the occurrence of any symptomatic blood clots, such as deep venous thrombosis or pulmonary embolism, within 45 days after starting the treatment. These conditions can be serious, as they involve blood clots forming in the veins or lungs, which can lead to complications if not treated effectively.

The trial is designed to ensure that both treatments are given under careful supervision, and participants will be monitored for any side effects or complications. The study will help determine the best approach to prevent blood clots in patients with lower limb injuries requiring immobilization, providing valuable information for future treatment options. Participants will be randomly assigned to receive either Rivaroxaban or LMWH, and some may receive a placebo to help compare the effectiveness of the treatments. The trial is expected to continue until September 2026.